JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1167)

VOLUNTARY ANNOUNCEMENT
PRESENTATION OF CLINICAL DATA OF GLECIRASIB IN COMBINATION WITH JAB-3312 AT THE 2023 ESMO CONGRESS

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the "**Company**" or "**Jacobio**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that, the clinical data of Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) was presented in the form of a proffered paper presentation at the 2023 European Society for Medical Oncology (ESMO) Congress (ESMO 2023).

- In terms of advanced non-small cell lung cancer (NSCLC) in all dose groups, the ORR (objective response rate) and the DCR (disease control rate) in the first-line therapy of Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) were 65.5% (38/58) and 100%, respectively, among which, in the dose group of 800 mg Glecirasib (once daily dose) in combination with 2 mg JAB-3312 (once daily for 1 week on, then 1 week off), the ORR was 86.7% (13/15) and the DCR was 100%.

- The clinical trial results validated the safety and efficacy of the combination therapy of Glecirasib and JAB-3312, which laid a foundation for further registrational clinical trials.

The Company presented a Phase I/IIa study of Glecirasib in combination with JAB-3312. The trial consisted of seven dose groups, including 400 mg and 800 mg Glecirasib in combination with JAB-3312 at different doses and dosing intervals, aiming to explore the safety, efficacy and tolerability through different dose groups, and to provide a basis for the subsequent registrational clinical trials. As of August 4, 2023, a total of 144 KRAS G12C mutant patients were enrolled, including 129 NSCLC patients, 14 patients with colorectal cancer, and 1 patient with pancreatic cancer.

Among the 129 NSCLC patients, 107 patients underwent at least one tumor assessment by RECIST 1.1 criteria, and 58 of them were first-line therapy patients (including 7 dose combinations); the ORR was 65.5% (38/58) and the DCR was 100%. The ORR was 86.7% (13/15) in the dose group[1] of 800 mg Glecirasib in combination with 2 mg JAB-3312. The median progression-free survival (mPFS) and duration of response are still under observation as the patients are still on treatment.

The incidence of grades 3 and 4 TRAEs (treatment-related adverse events) was 39.6% across all the dose groups, whereas the incidence of grades 3 and 4 TRAEs was 36.7% in the dose group[1] of 800 mg Glecirasib in combination with 2 mg JAB-3312.

Please visit the official website of the congress: https://www.esmo.org/ for more information.

About Glecirasib

Glecirasib (JAB-21822) is a KRAS G12C inhibitor independently developed by Jacobio. Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors harbouring KRAS G12C mutation, including a pivotal clinical trial to treat NSCLC in China, a monotherapy study for STK11 co-mutated NSCLC in the front-line setting; combination therapy trials with SHP2 inhibitor JAB-3312, and the combination therapy of Glecirasib with Cetuximab in treatment of colorectal cancer.

About JAB-3312

JAB-3312 is a highly selective SHP2 inhibitor with best-in-class potential. Jacobio is currently conducting multiple clinical trials of JAB-3312 in China, the United States and Europe, including combination therapy trials with Glecirasib and other projects.

About Jacobio

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our immunostimulatory antibody-drug conjugate (iADC) Platform.

Note: [1] once daily for 1 week on, and 1 week off

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that Glecirasib (JAB-21822) and JAB-3312 will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Please visit www.jacobiopharma.com for more information.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, October 23, 2023

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.